Literature DB >> 1849042

Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography.

F Jehl1, E Quoix, D Leveque, G Pauli, F Breillout, A Krikorian, H Monteil.   

Abstract

The pharmacokinetics and metabolism of Navelbine (NVB) were investigated in 20 patients by a specific high performance liquid chromatographic methodology allowing the monitoring of NVB, deacetyl-NVB, and N-oxide NVB. After the i.v. (15 min) administration of 30 mg/m2 of drug, blood and urine samples were collected for, respectively, 144 and 48 h. NVB is characterized by a three compartmental kinetics, with a Cmax of 1130 +/- 139 (SEM) ng/ml. The total body clearance and apparent volume of distribution, as defined by high performance liquid chromatography, are 1.26 +/- 0.09 liter/h/kg (48.6 +/- 4.1 liters/h/m2) and 75.6 +/- 9.2 liters/kg (2918.4 +/- 307.2 liters/m2). No metabolite could be detected in serum; the urinary excretion of NVB represented 11% of the administered dose. Deacetyl-NVB could be identified as a minor urinary metabolite when no N-oxide NVB appeared in the urine samples. Two additional peaks appeared in most of urinary chromatograms as trace amounts. Thus, the major pathway of NVB, as for other Vinca alkaloids, should be hepatic clearance, as biliary elimination and/or hepatic biotransformation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1849042

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of vinorelbine.

Authors:  D Levêque; F Jehl
Journal:  Clin Pharmacokinet       Date:  1996-09       Impact factor: 6.447

3.  Long-term pharmacokinetics of doxorubicin HCl stealth liposomes in patients after polychemotherapy with vinorelbine, cyclophosphamide and prednisone (CCVP).

Authors:  W Linkesch; M Weger; I Eder; H W Auner; C Pernegg; C Kraule; M J Czejka
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2001 Jul-Sep       Impact factor: 2.441

Review 4.  Vinorelbine: a review of its use in elderly patients with advanced non-small cell lung cancer.

Authors:  Monique P Curran; Greg L Plosker
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

5.  Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials.

Authors:  Laurent Nguyen; Brigitte Tranchand; Christian Puozzo; Philippe Variol
Journal:  Br J Clin Pharmacol       Date:  2002-05       Impact factor: 4.335

Review 6.  New oral chemotherapeutic agents for lung cancer.

Authors:  E M Bengtson; J R Rigas
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 7.  Vinorelbine. A review of its pharmacological properties and clinical use in cancer chemotherapy.

Authors:  K L Goa; D Faulds
Journal:  Drugs Aging       Date:  1994-09       Impact factor: 3.923

Review 8.  Preclinical and clinical pharmacology of vinca alkaloids.

Authors:  X J Zhou; R Rahmani
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 9.  The current and future place of vinorelbine in cancer therapy.

Authors:  E Cvitkovic; J Izzo
Journal:  Drugs       Date:  1992       Impact factor: 9.546

10.  Biliary elimination and pharmacokinetics of vinorelbine in micropigs.

Authors:  D Levêque; M Merle-Melet; L Bresler; J P Didelot; J P Aymard; J Wihlm; F Jehl
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.